Avila Therapeutics, a biotechnology company, has appointed Andrew Hirsch as its first chief financial officer (CFO). Hirsch joins Avila from Biogen Idec where he spent the past 10 years in a number of roles of increasing responsibility – most recently as vice president of corporate strategy and merger and acquisition (M&A).
Hirsch’s prior roles during his tenure at Biogen Idec included responsibilities in the finance organisation for corporate planning, budget development and management, and investor relations.
Hirsch led business development for a software start-up company and spent several years in management consulting at Stern Stewart & Co and The Parthenon Group. He graduated from the University of Pennsylvania with a BA in Economics and holds a MBA from The Tuck School at Dartmouth College.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.